Xilio Therapeutics (XLO) Price & Analysis

Compare

201 Followers

XLO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.62 - $1.70

Previous CloseN/A

Volume162.24K

Average Volume (3M)730.37K

Market Cap

$41.25M

Enterprise Value-$48.41M

Total Cash (Recent Filing)$89.07M

Total Debt (Recent Filing)$7.86M

Price to Earnings (P/E)―

Beta-0.17

Next Earnings

Nov 06, 2025

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding51,827,910

10 Day Avg. Volume314,186

30 Day Avg. Volume730,369

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.17

Enterprise Value/Revenue-5.22

Enterprise Value/Gross Profit-5.22

Enterprise Value/Ebitda0.88

Forecast

1Y Price Target

$2.00

Price Target Upside150.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe recently added 150 mg Q6W vilastobart cohort represents upside to the 100 mg Q6W cohort's already promising efficacy and safety profile.

Future ProspectsXilio is also advancing XTX501 (a masked bispecific PD-1/IL-2) towards a mid-2026 IND in various solid tumor types.

Product DevelopmentVilastobart is positioned for development and commercial success in the relapsed/refractory and earlier-line colorectal cancer settings.

Bears Say

Financial HealthThe company ended the quarter with $121.6M in cash and cash equivalents, which should sustain operations into 3Q26.

Partnership NeedsFinding the right partner quickly is critical for both the asset and the company.

Xilio Therapeutics News

Xilio Therapeutics announces initiation of Phase 2 trial for efarindodekin alfa

Xilio Therapeutics (XLO) announced the initiation of patient dosing in Phase 2 of an ongoing Phase 1/2 clinical...

20d ago

XLO

GILD

Xilio Therapeutics sees cash runway into 1Q27

As of June 30, 2025, Xilio had cash and cash equivalents of $121.6M. Based on its current operating...

20d ago

XLO

Xilio Therapeutics Initiates Phase 2 Trial for XTX301

Xilio Therapeutics ( ($XLO) ) has issued an announcement. On September 9, 2025, Xilio Therapeutics announced the initiation...

20d ago

XLO

Xilio Therapeutics Faces Nasdaq Equity Compliance Challenge

Xilio Therapeutics ( ($XLO) ) has shared an update. On August 22, 2025, Xilio Therapeutics, Inc. received a...

1M ago

XLO

Xilio Therapeutics Reports Strong Pipeline Progress and Financial Results

Xilio Therapeutics Inc ( ($XLO) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

XLO

Promising Future for Xilio Therapeutics: Strong Financial Position and Encouraging Trial Results Support Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on XLO stock, giving a Buy rating on...

2M ago

XLO

Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year

Reports Q2 revenue $8.084M vs $2.357M last year. “During the second quarter, we continued to make strong progress...

2M ago

XLO

Snap downgraded, Leidos upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

ALC

Xilio Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Xilio Therapeutics (XLO) with an Outperform rating and $72 price target The company’s lead...

2M ago

XLO

Xilio Therapeutics Expands Authorized Shares at Annual Meeting

Xilio Therapeutics ( ($XLO) ) has issued an announcement. On June 10, 2025, Xilio Therapeutics held its annual...

4M ago

XLO

Xilio Therapeutics Expands Board with New Director

Xilio Therapeutics ( ($XLO) ) has provided an announcement. On June 10, 2025, Xilio Therapeutics expanded its Board...

4M ago

XLO

Xilio Therapeutics Announces $50M Public Offering

Xilio Therapeutics ( ($XLO) ) has issued an announcement. On June 2, 2025, Xilio Therapeutics announced the pricing...

4M ago

XLO

Xilio Therapeutics announces pricing of $50M public offering

Xilio Therapeutics (XLO) announced the pricing of an underwritten public offering of pre-funded warrants to purchase 66,676,000 shares...

4M ago

XLO

Xilio Therapeutics Presents Phase 2 Trial Data Update

Xilio Therapeutics ( ($XLO) ) just unveiled an update. On May 31, 2025, Xilio Therapeutics announced updated data...

4M ago

XLO

XLO FAQ

What was Xilio Therapeutics’s price range in the past 12 months?

Xilio Therapeutics lowest stock price was $0.61 and its highest was $1.70 in the past 12 months.

What is Xilio Therapeutics’s market cap?

Xilio Therapeutics’s market cap is $41.25M.

When is Xilio Therapeutics’s upcoming earnings report date?

Xilio Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 38 days.

How were Xilio Therapeutics’s earnings last quarter?

Xilio Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.079 by -$0.081.

Is Xilio Therapeutics overvalued?

According to Wall Street analysts Xilio Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Xilio Therapeutics pay dividends?

Xilio Therapeutics does not currently pay dividends.

What is Xilio Therapeutics’s EPS estimate?

Xilio Therapeutics’s EPS estimate is -0.03.

How many shares outstanding does Xilio Therapeutics have?

Xilio Therapeutics has 51,827,910 shares outstanding.

What happened to Xilio Therapeutics’s price movement after its last earnings report?

Xilio Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.079. Following the earnings report the stock price went down -1.408%.

Which hedge fund is a major shareholder of Xilio Therapeutics?

Currently, no hedge funds are holding shares in XLO

Xilio Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-277.74%

Trailing 12-Months

Asset Growth

48.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xilio Therapeutics

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics (XLO) Earnings & Revenues

Historic Earnings Reports

XLO Stock 12 Month Forecast

Average Price Target

$2.00

▲(150.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.65,0.7538461538461538,0.8576923076923078,0.9615384615384616,1.0653846153846154,1.1692307692307693,1.273076923076923,1.376923076923077,1.4807692307692308,1.5846153846153848,1.6884615384615387,1.7923076923076926,1.896153846153846,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.65,0.7538461538461538,0.8576923076923078,0.9615384615384616,1.0653846153846154,1.1692307692307693,1.273076923076923,1.376923076923077,1.4807692307692308,1.5846153846153848,1.6884615384615387,1.7923076923076926,1.896153846153846,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.65,0.7538461538461538,0.8576923076923078,0.9615384615384616,1.0653846153846154,1.1692307692307693,1.273076923076923,1.376923076923077,1.4807692307692308,1.5846153846153848,1.6884615384615387,1.7923076923076926,1.896153846153846,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.7,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.96,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >